UNSPSC 51141581: Taltrimide

This classification denotes an anticonvulsant agent with the molecular formula C13H16N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQ74U9QR5D, chemically known as 2h-isoindole-2-ethanesulfonamide, 1,3-dihydro-n-(1-methylethyl)-1,3-dioxo- but generally known as taltrimide, which bears US NIH Compound Identifier 71248. European Medicines Agency schedules Taltrimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10817MIG.

UNSPSC 51141581 Taltrimide is a Commodity code that in practice maps to pharmaceutical and medical supply procurement by state and local health agencies, though recent solicitation activity under this code is minimal. The single recent opportunity recorded shows a county health department procuring naloxone and drug deactivation systems—products outside the nominal scope of taltrimide (a pharmaceutical intermediate) but tagged to this code in the state procurement system. State and local governments under this code are primarily county health departments and community health agencies managing emergency response and harm-reduction inventory. The absence of multiple recent solicitations suggests either light activity under this specific commodity code or misclassification of health-supply buys across broader pharmaceutical or medical-supply families.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the deadline was July 26, 2023 (note the date discrepancy in the source record). The contract included a two-year initial term with a one-year renewal option, fixed-fee pricing, e-procurement portal submission, drug-free workplace and E-Verify compliance, and potential FEMA funding with associated federal environmental compliance requirements. No explicit disadvantaged-enterprise set-asides were named. This appears to be the sole recent state or local opportunity indexed under this code; business development professionals should verify whether their offerings align with the pharmaceutical or medical-supply classification or whether broader family-level codes in the drug, medical device, or public-health-supplies space offer more robust pipeline visibility.